INS and breast carcinoma: In breast cancer cells, metformin exerted anticancer effects by changing the metabolic milieu and reducing the circulating insulin levels by improving insulin resistance with reduced insulin/IGF-I receptor-mediated phosphoinositide 3-kinases (PI3K) signaling [111].